CA2157902A1 - Tumour targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides - Google Patents

Tumour targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides

Info

Publication number
CA2157902A1
CA2157902A1 CA002157902A CA2157902A CA2157902A1 CA 2157902 A1 CA2157902 A1 CA 2157902A1 CA 002157902 A CA002157902 A CA 002157902A CA 2157902 A CA2157902 A CA 2157902A CA 2157902 A1 CA2157902 A1 CA 2157902A1
Authority
CA
Canada
Prior art keywords
enantiomeric
residue
precursor
reagent
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002157902A
Other languages
English (en)
French (fr)
Inventor
Christopher Douglas Valiant Black
Robert Allen Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2157902A1 publication Critical patent/CA2157902A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002157902A 1993-03-10 1994-03-10 Tumour targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides Abandoned CA2157902A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3308393A 1993-03-10 1993-03-10
US033083 1993-03-10
PCT/US1994/002610 WO1994020523A1 (en) 1993-03-10 1994-03-10 Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides

Publications (1)

Publication Number Publication Date
CA2157902A1 true CA2157902A1 (en) 1994-09-15

Family

ID=21868470

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002157902A Abandoned CA2157902A1 (en) 1993-03-10 1994-03-10 Tumour targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides

Country Status (5)

Country Link
EP (1) EP0691981A1 (ja)
JP (1) JPH08512019A (ja)
AU (1) AU6402594A (ja)
CA (1) CA2157902A1 (ja)
WO (1) WO1994020523A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU672951B2 (en) * 1992-05-07 1996-10-24 Ge Healthcare As Complexing agents and targeting immunoreagents
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
PT2415776T (pt) * 1998-08-10 2016-07-07 Novartis Ag Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1264603B8 (en) * 2001-06-10 2010-03-03 Noxxon Pharma AG Use of L-polynucleotides for in vivo imaging
EP1288309A1 (de) * 2001-08-30 2003-03-05 Noxxon Pharma AG Verfahren zur Markierung von L-Nukleinsäuren
US6942972B2 (en) * 2001-10-24 2005-09-13 Beckman Coulter, Inc. Efficient synthesis of protein-oligonucleotide conjugates
EP1306382A1 (de) * 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ATE469164T1 (de) * 2001-10-26 2010-06-15 Noxxon Pharma Ag Modifizierte l-nukleinsäure
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
EP1572095B1 (en) 2002-09-13 2015-06-10 Novartis AG Beta-l-2'-deoxynucleosides for use in the treatment of resistant hbv strains

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5158880A (en) * 1988-09-23 1992-10-27 E. I. Du Pont De Nemours And Company Process for preparing solid perfluorocarbon polymer supports having attached perfluorocarbon-substituted ligand or binder
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods

Also Published As

Publication number Publication date
WO1994020523A1 (en) 1994-09-15
EP0691981A1 (en) 1996-01-17
JPH08512019A (ja) 1996-12-17
AU6402594A (en) 1994-09-26

Similar Documents

Publication Publication Date Title
US5733523A (en) Targeted delivery of a therapeutic entity using complementary oligonucleotides
CA2150477A1 (en) Sequential targeting of tumor sites with oligonucleotide conjugates of antibody and complementary oligonucleotide conjugates of chelated radionuclide
CA2157902A1 (en) Tumour targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
JP3143506B2 (ja) 治療用物質の標的送達用医薬組成物
JP2009197024A (ja) 金属複合体及びオリゴヌクレオチドから作られた接合体、該接合体を含む薬剤、放射線診断におけるそれらの使用並びにそれらの製造のための方法
US5746997A (en) Radiohalogenation of oligonucleotides via trialkylstannylaryl conjugates
US20020077306A1 (en) Conjugates made of metal complexes and oligonucleotides, agents containing the conjugates, their use in radiodiagnosis as well as process for their production
EP0675737A1 (en) Immunoreactive reagents employing dihydrofolate reductase
EP0613379B1 (en) Therapeutic compounds
CA2164518A1 (en) Immunoreactive reagents employing monoamine oxidase
CA2154896A1 (en) Immunoreactive reagents employing heterodimers
US7713528B1 (en) Method for in vivo delivery of active compounds using reagent conjugate
WO1997033626A1 (en) Novel chelators and compositions prepared therewith
Gambhir New Gene Based Probes for Imaging Breast Cancer with PET
AU2036099A (en) Conjugates made of metal complexes and oligonucleotides

Legal Events

Date Code Title Description
FZDE Discontinued